The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs

Pharmacology and Therapeutics

Volumn 124, Issue 3, 2009, Pages 309-323

  Villalón, Carlos M ^a   Olesen, Jes ^b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antimigraine drug; CGRP; CGRP receptor antagonists; Drug development; Headache; Migraine; Olcegepant; Telcagepant

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADRENOMEDULLIN; ALPHA CALCITONIN GENE RELATED PEPTIDE; AMYLIN; ANANDAMIDE; ANTIMIGRAINE AGENT; AZEPEXOLE; BIBN 4096; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE 1; CALCITONIN GENE RELATED PEPTIDE 2 RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CAPSAZEPINE; GLYCERYL TRINITRATE; NITRIC OXIDE; OLCEGEPANT; PLACEBO; PNU 142633; RIZATRIPTAN; SEROTONIN 1D AGONIST; TELCAGEPANT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BRAIN BLOOD FLOW; BREATHING RATE; CARDIOVASCULAR SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FLUSHING; FOREARM BLOOD FLOW; GENOTYPE ENVIRONMENT INTERACTION; HAND PARESTHESIA; HUMAN; LABORATORY TEST; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; OPTIMAL DRUG DOSE; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PULSE RATE; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; RISK FACTOR; SENSORY DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; XEROSTOMIA;

ANALGESICS; ANIMALS; AZEPINES; BRAIN; CALCITONIN GENE-RELATED PEPTIDE; DIPEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; IMIDAZOLES; MIGRAINE DISORDERS; QUINAZOLINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 70450223684     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.09.003     Document Type: Review

References (196)

1. Afridi S.K., Giffin N.J., Kaube H., Friston K.J., Ward N.S., Frackowiak R.S., et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol 62 (2005) 1270-1275
2. Afridi S.K., Kaube H., and Goadsby P.J. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110 (2004) 675-680
3. Akerman S., Kaube H., and Goadsby P.J. Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 140 (2003) 718-724
4. Akerman S., Kaube H., and Goadsby P.J. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 309 (2004) 56-63
5. Amara S., Arriza J., Leff S., Swanson L., Evans R., and Rosenfeld M. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229 (1985) 1094-1097
6. Anderson L.E., and Seybold V.S. Calcitonin gene-related peptide regulates gene transcription in primary afferent neurons. J Neurochem 91 (2004) 1417-1429
7. Andlin-Sobocki P., Jonsson B., Wittchen H.U., and Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 12 Suppl 1 (2005) 1-27
8. Arulmani U., MaassenVanDenBrink A., Villalón C.M., and Saxena P.R. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500 (2004) 315-330
9. Arulmani U., Schuijt M.P., Heiligers J.P.C., Willems E.W., Villalón C.M., and Saxena P.R. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on α-CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol 94 (2004) 291-297
10. Banerjee S., Evanson J., Harris E., Lowe S.L., Thomasson K.A., and Porter J.E. Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding. BMC Pharmacol 15 (2006) 6-9
11. Bell D., and McDermott B.J. Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Pharmacol Rev 48 (1996) 253-288
12. Bigal M.E., and Lipton R.B. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 27 (2009) 321-334
13. Blau J.N. Migraine postdromes: symptoms after attacks. Cephalalgia 11 (1991) 229-231
14. Blau J.N. Migraine: theories of pathogenesis. Lancet 339 (1992) 1202-1207
15. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129 (2000) 501-508
16. Bowen E., Schmidt T., Firm C., Russo A., and Durham P. Tumor necrosis factor-α stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem 96 (2006) 65-77
17. Brain S., Williams T., Tippins J., Morris H., and MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 313 (1985) 54-56
18. Brzozowski T., Konturek P.C., Pajdo R., Kwiecien S., Sliwowski Z., Drozdowicz D., et al. Importance of brain-gut axis in the gastroprotection induced by gastric and remote preconditioning. J Physiol Pharmacol 55 (2004) 165-177
19. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89 (2001) 107-110
20. Chang L., and Karin M. Mammalian MAP kinase signaling cascades. Nature 410 (2001) 37-40
21. Chang Y., Stover S.R., and Hoover D.B. Regional localization and abundance of calcitonin gene-related peptide receptors in guinea pig heart. J Mol Cell Cardiol 33 (2001) 745-754
22. Cheng L., Khan M., and Mudge A. Calcitonin gene-related peptide promotes Schwann cell proliferation. J Cell Biol 129 (1995) 789-796
23. Committee. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 Suppl 1 (2004) 9-160
24. Conner A.C., Hay D.L., Howitt S.G., Kilk K., Langel U., Wheatley M., et al. Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans 30 (2002) 451-455
25. Coupe M.O., Mak J.C., Yacoub M., Oldershaw P.J., and Barnes P.J. Autoradiographic mapping of calcitonin gene-related peptide receptors in human and guinea pig hearts. Circulation 81 (1990) 741-747
26. Dahlöf C. Integrating the triptans into clinical practice. Curr Opin Neurol 15 (2002) 317-322
27. Davis C.D., and Xu C. The tortuous road to an ideal CGRP function blocker for the treatment of migraine. Curr Top Med Chem 8 (2008) 1468-1479
28. De Hoon J.N., Pickkers P., Smits P., Struijker-Boudier H.A., and Van Bortel L.M. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 73 (2003) 312-321
29. 8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J Pharmacol Exp Ther 254 (1990) 123-128
30. Dennis T., Fournier A., St. Pierre S., and Quirion R. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues: evidence for receptor multiplicity. J Pharmacol Exp Ther 251 (1989) 718-725
31. Diener H.C., and May A. Positron emission tomography studies in acute migraine attacks. In: Sandler M., Ferrari M., and Harnett S. (Eds). Migraine: pharmacology and genetics (1996), Chapman and Hall, London 109-116
32. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs 2 (2001) 1261-1268
33. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129 (2000) 420-423
34. Durham P.L. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache 8 (2008) 1269-1275
35. Edmeads J. History of migraine treatment. Can J Clin Pharmacol 6 Suppl A (1999) 5A-8A
36. Edvinsson L., Alm R., Shaw D., Rutledge R.Z., Koblan K.S., Longmore J., et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 434 (2002) 49-53
37. Edvinsson L., Ekman R., Jansen I., McCulloch J., and Uddman R. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7 (1987) 720-728
38. Edvinsson L., Nilsson E., and Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150 (2007) 633-640
39. Edvinsson L., Sams A., Jansen-Olesen I., Tajti J., Kane S.A., Rutledge R.Z., et al. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol 415 (2001) 39-44
40. Evans B.N., Rosenblatt M.I., Mnayer L.O., Oliver K.R., and Dickerson I.M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 275 (2000) 31438-31443
41. Fischer M.J., Koulchitsky S., and Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 25 (2005) 5877-5883
42. Fiscus R., Zhou H., Wang X., Han C., Ali S., Joyce C., et al. Calcitonin gene-related peptide (CGRP)-induced cyclic AMP, cyclic GMP and vasorelaxant responses in rat thoracic aorta are antagonized by blockers of endothelium-derived relaxant factor (EDRF). Neuropeptides 20 (1991) 133-143
43. Fitzsimmons T.J., Zhao X., and Wank S.A. The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function. J Biol Chem 278 (2003) 14313-14320
44. Foord S.M., and Marshall F.H. RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sci 20 (1999) 184-187
45. Gallai V., Sarchielli P., Floridi A., Franceschini M., Codini M., Glioti G., et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15 (1995) 384-390
46. 1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 23 (2003) 287-292
47. Giffin N.J., Ruggiero L., Lipton R.B., Silberstein S.D., Tvedskov J.F., Olesen J., et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 60 (2003) 935-940
48. Goadsby P.J. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13 (2007) 39-44
49. 1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122 (2003) 491-498
50. Goadsby P.J., and Edvinsson L. Sumatriptan reverses the change in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 11 (1991) 3-4
51. Goadsby P.J., Edvinsson L., and Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23 (1988) 193-196
52. Goadsby P.J., Edvinsson L., and Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28 (1990) 183-187
53. 1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125 (2002) 1392-1401
54. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Engl J Med 346 (2002) 257-270
55. Goldstein D.J., Roon K.I., Offen W.W., Ramadan N.M., Phebus L.A., Johnson K.W., et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358 (2001) 1230-1234
56. 1D agonist, in patients with acute migraine. Cephalalgia 21 (2001) 727-732
57. Gozalov A., Jansen-Olesen I., Klaerke D., and Olesen J. Role of K ATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. Headache 48 (2008) 1202-1213
58. Gupta S., Mehrotra S., Villalón C.M., Garrelds I.M., de Vries R., van Kats J.P., et al. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 530 (2006) 107-116
59. Gursoy-Ozdemir Y., Qiu J., Matsuoka N., Bolay H., Bermpohl D., Jin H., et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113 (2004) 1447-1455
60. Guzik T., Korbut R., and Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54 (2003) 469-487
61. Hagner S., Haberberger R.V., Overkamp D., Hoffmann R., Voigt K.H., and McGregor G.P. Expression and distribution of calcitonin receptor-like receptor in human hairy skin. Peptides 23 (2002) 109-116
62. Hagner S., Knauer J., Haberberger R., Goke B., Voigt K., and McGregor G.P. Calcitonin receptor-like receptor is expressed on gastrointestinal immune cells. Digestion 66 (2002) 197-203
63. Hagner S., Stahl U., Knoblauch B., McGregor G.P., and Lang R.E. Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell Tissue Res 310 (2002) 41-50
64. Hargreaves R. New migraine and pain research. Headache 47 (2007) S26-S43
65. Hargreaves K.M., Jackson D.L., and Bowles W.R. Adrenergic regulation of capsaicin-sensitive neurons in dental pulp. J. Endod 29 (2003) 397-399
66. Hasbak P., Opgaard O.S., Eskesen K., Schifter S., Arendrup H., Longmore J., et al. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 304 (2003) 326-333
67. Hay D.L., Christopoulos G., Christopoulos A., Poyner D.R., and Sexton P.M. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 67 (2005) 1655-1665
68. Hay D.L., Christopoulos G., Christopoulos A., and Sexton P.M. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl] amino]-1-[(3, 5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1, 4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol Pharmacol 70 (2006) 1984-1991
69. 8-37 and BIBN4096BS. Br J Pharmacol 140 (2003) 477-486
70. Hay D.L., Poyner D.R., and Quirion R. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol Rev 60 (2008) 143-145
71. Hay D.L., Poyner D.R., and Sexton P.M. GPCR modulation by RAMPs. Pharmacol Ther 109 (2006) 173-197
72. Ho T.W., Ferrari M.D., Dodick D.W., Galet V., Kost J., Fan X., et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372 (2008) 2115-2123
73. Ho T.W., Ferrari M.D., Dodick D.W., Shapiro R.E., Diener H.C., Lucas S., et al. Clinical profile of the novel oral CGRP receptor antagonist telcagepant for the acute treatment of migraine in two phase 3 randomized placebo controlled trials. Neurology 72 (2009) A250
74. Ho T.W., Mannix L.K., Fan X., Assaid C., Furtek C., Jones C.J., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70 (2008) 1304-1312
75. Hoffmann O., Keilwerth N., Bille M.B., Reuter U., Angstwurm K., Schumann R.R., et al. Triptans reduce the inflammatory response in bacterial meningitis. J Cereb Blood Flow Metab 22 (2002) 988-996
76. Hong K.W., Yoo S.E., Yu S.S., Lee J.Y., and Rhim B.Y. Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am J Physiol 270 (1996) H317-H323
77. 1 receptor activation: a novel approach towards the design of new anti-migraine compounds. Cephalalgia 21 (2001) 268-269
78. Iovino M., Feifel U., Yong C.L., Wolters J.M., and Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 24 (2004) 645-656
79. Iversen H.K., Nielsen T.H., Olesen J., and TfeltHansen P. Arterial responses during migraine headache. Lancet 336 (1990) 837-839
80. Iversen H.K., Olesen J., and TfeltHansen P. Intravenous nitroglycerin as an experimental-model of vascular headache-basic characteristics. Pain 38 (1989) 17-24
81. Jansen-Olesen I., Mortensen A., and Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16 (1996) 310-316
82. Jarvikallio A., Harvima I.T., and Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 295 (2003) 2-7
83. Jensen R., and Stovner L.J. Epidemiology and comorbidity of headache. Lancet Neurol 7 (2008) 354-361
84. Ji R.R. Mitogen-activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs 5 (2004) 71-75
85. Ji R.R. Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr Drug Targets Inflamm Allergy 3 (2004) 299-303
86. Juaneda C., Dumont Y., and Quirion R. The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 21 (2000) 432-438
87. Juhasz G., Zsombok T., Modos E.A., Olajos S., Jakab B., Nemeth J., et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106 (2003) 461-470
88. Juhl L., Edvinsson L., Olesen J., and Jansen-Olesen I. Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol 567 (2007) 117-124
89. Kaminska B. MAPK signaling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochem Biophys Acta 1754 (2005) 253-262
90. Kangrga I., Larew J.S., and Randic M. The effects of substance P and calcitonin gene-related peptide on the efflux of endogenous glutamate and aspartate from the rat spinal dorsal horn in vitro. Neurosci Lett 108 (1990) 155-160
91. Kapoor K., Arulmani U., Heiligers J.P., Garrelds I.M., Willems E.W., Doods H., et al. Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol 140 (2003) 329-338
92. Kapoor K., Arulmani U., Heiligers J.P., Willems E.W., Doods H., Villalón C.M., et al. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur J Pharmacol 475 (2003) 69-77
93. Kaygisiz Z., Erksap N., Uyar R., Kabadere S., Kabadere T.E., and Dernek S. The effect of adrenomedullin, amylin fragment 8-37 and calcitonin gene-related peptide on contractile force, heart rate and coronary perfusion pressure in isolated rat hearts. Acta Physiol Hung 90 (2003) 133-146
94. Kirchmann M., Thomsen L.L., and Olesen J. The CACNA1A and ATP1A2 genes are not involved in dominantly inherited migraine with aura. Am J Med Genet Part B-Neuropsych Genet 141B (2006) 250-256
95. + channels in CGRP-induced dilatation of basilar artery in vivo. Am J Physiol 265 (1993) H581-H585
96. Koulchitsky S., Fischer M.J., De C.R., Schlechtweg P.M., and Messlinger K. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat-possible implications for the pathophysiology of headaches. J Neurophysiol 92 (2004) 1320-1328
97. Koulchitsky S., Fischer M.J., and Messlinger K. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 29 (2009) 408-417
98. Kuwasako K., Cao Y.N., Nagoshi Y., Tsuruda T., Kitamura K., and Eto T. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. Mol Pharmacol 65 (2004) 207-213
99. Lassen L.H., Ashina M., Christiansen I., Ulrich V., and Olesen J. Nitric oxide synthase inhibition in migraine. Lancet 349 (1997) 401-402
100. Lassen L.H., Haderslev P.A., Jacobsen V.B., Iversen H.K., Sperling B., and Olesen J. CGRP may play a causative role in migraine. Cephalalgia 22 (2002) 54-61
101. Lassen L.H., Pedersen P.A., Sperling B., Iversen H., and Olesen J. Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs. Eur J Neurol 5 Suppl 3 (1998) 63
102. Lassen L.H., Thomsen L.L., and Olesen J. Histamine induces migraine via the H-1-receptor-support for the NO hypothesis of migraine. Neuroreport 6 (1995) 1475-1479
103. Lauritzen M. Long-lasting reduction of cortical blood flow of the brain after spreading depression with preserved autoregulation and impaired CO2 response. J Cereb Blood Flow Metab 4 (1984) 546-554
104. Lennerz J.K., Rühle V., Ceppa E.P., Neuhuber W.L., Bunnett N.W., Grady E.F., et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507 (2008) 1277-1299
105. Levy D., Burstein R., and Strassman A.M. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58 (2005) 698-705
106. 1B/1D receptor agonists. Proc Nat Acad Sci USA 101 (2004) 4274-4279
107. Li Y.J., and Peng J. The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. Eur J Pharmacol 442 (2002) 173-177
108. Li J., Vause C., and Durham P. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 1196 (2008) 22-32
109. Link A.S., Kuris A., and Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 9 (2008) 5-12
110. Ma W., Chabot J.G., Powell K.J., Jhamandas K., Dickerson I.M., and Quirion R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 120 (2003) 677-694
111. Mallee J.J., Salvatore C.A., LeBourdelles B., Oliver K.R., Longmore J., Koblan K.S., et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 277 (2002) 14294-14298
112. 1D receptor agonist PNU-142633. Cephalalgia 22 (2002) 799-806
113. McCulloch J., Uddman R., Kingman T.A., and Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 83 (1986) 5731-5735
114. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
115. Morara S., Rosina A., Provini L., Forloni G., Caretti A., and Wimalawansa S.J. Calcitonin gene-related peptide receptor expression in the neurons and glia of developing rat cerebellum: an autoradiographic and immunohistochemical analysis. Neuroscience 100 (2000) 381-391
116. 2+ responses in cultured astrocytes and in Bergmann glial cells from cerebellar slices. Eur J Neurosci 28 (2008) 2213-2220
117. Moreno M.J., Abounader R., Hebert E., Doods H., and Hamel E. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 42 (2002) 568-576
118. Moreno M.J., Terron J.A., Stanimirovic D.B., Doods H., and Hamel E. Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins (RAMPs) in human brain microvascular and astroglial cells in culture. Neuropharmacology 42 (2002) 270-280
119. Mulderry P., Ghatei M., Spokes R., Jones P.M., Pierson A.M., Hamid Q.A., et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 25 (1988) 195-205
120. Naik A., Tandan S., Kumar D., and Dudhgaonkar S. Nitric oxide and its modulators in chronic constriction injury-induced neuropathic pain in rats. Eur J Pharmacol 530 (2006) 59-69
121. Obata K., and Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci 74 (2004) 2643-2653
122. Ohtori S., Takahashi K., Chiba T., Yamagata M., Sameda H., and Moriya H. Substance P and calcitonin gene-related peptide immunoreactive sensory DRG neurons innervating the lumbar intervertebral discs in rats. Ann Anat 184 (2002) 235-240
123. Oku R., Satoh M., Fujii N., Otaka A., Yajima H., and Takagi H. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 403 (1987) 350-354
124. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120 (2008) 157-171
125. Olesen, J. (Editor) (2010). Role of Calcitonin Gene-related Peptide (CGRP) and Adrenomedullin (ADM) in Migraine. Oxford University Press, Oxford, In Press.
126. Olesen J., Burstein R., Ashina M., and TfeltHansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8 (2009) 679-690
127. Olesen J., Diener H.C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., et al. Calcitonin gene-related peptide receptor antagonist BIBN4096 BS for the acute treatment of migraine. N Engl J Med 350 (2004) 1104-1110
128. Olesen J., Lauritzen M., TfeltHansen P., Henriksen L., and Larsen B. Spreading cerebral oligemia in classical and normal cerebral blood-flow in common migraine. Headache 22 (1982) 242-248
129. Olesen J., Tfelt-Hansen P., Henriksen L., and Larsen B. The common migraine attack may not be initiated by cerebral ischaemia. Lancet 2 (1981) 438-440
130. Olesen J., Thomsen L.L., and Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 15 (1994) 149-153
131. Oliver K.R., Wainwright A., Edvinsson L., Pickard J.D., and Hill R.G. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22 (2002) 620-629
132. Oliver K.R., Wainwright A., Kinsey A.M., Heavens R.P., Sirinathsinghji D.J., and Hill R.G. Regional and cellular localization of calcitonin gene-related peptide-receptor component protein mRNA in the guinea-pig central nervous system. Brain Res Mol Brain Res 66 (1999) 205-210
133. Ottosson A., and Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17 (1997) 166-174
134. Paone D.V., Shaw A.W., Nguyen D.N., Burgey C.S., Deng J.Z., Kane S.A., et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R, 6 S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4, 5-b]pyridin-1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem 50 (2007) 5564-5567
135. Parameswaran N., Disa J., Spielman W., Brooks D., Nambi P., and Aiyar N. Activation of multiple mitogen-activated protein kinases by recombinant calcitonin gene-related peptide receptor. Eur J Pharmacol 389 (2000) 125-130
136. Pedersen-Bjergaard U., Nielsen L.B., Jensen K., Edvinsson L., Jansen I., and Olesen J. Calcitonin gene-related peptide, neurokinin-a and substance-p-effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 12 (1991) 333-337
137. Petersen K.A., Birk S., Doods H., Edvinsson L., and Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 143 (2004) 697-704
138. Petersen K.A., Birk S., Lassen L.H., Kruuse C., Jonassen O., Lesko L., et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25 (2005) 139-147
139. Petersen K.A., Lassen L.H., Birk S., Lesko L., and Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77 (2005) 202-213
140. Petersen K.A., Nilsson E., Olesen J., and Edvinsson L. Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 25 (2005) 424-432
141. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 4 (2003) 386-398
142. Powell K.J., Ma W., Sutak M., Doods H., Quirion R., and Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol 131 (2000) 875-884
143. 2 subdivision?. Trends Pharmacol Sci 22 (2001) 223
144. Poyner D.R., Sexton P.M., Marshall I., Smith D.M., Quirion R., Born W., et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54 (2002) 233-246
145. Ramadan N.M., and Buchanan T.M. New and future migraine therapy. Pharmacol Ther 112 (2006) 199-212
146. 1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia 23 (2003) 776-785
147. Rosenfeld M.G., Mermod J.J., Amara S.G., Swanson L.W., Sawchenko P.E., Rivier J., et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304 (1983) 129-135
148. Rossi S.G., Dickerson I.M., and Rotundo R.L. Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J Biol Chem 278 (2003) 24994-25000
149. Rudolf K., Eberlein W., Engel W., Pieper H., Entzeroth M., Hallermayer G., et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3, 5-Dibromo-N-[[4-(3, 4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L -lysyl]-4-(4-pyridinyl) piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 48 (2005) 5921-5931
150. Ruiz de Velasco I., Gonzalez N., Etxeberria Y., and Garcia-Monco J.C. Quality of life in migraine patients: a qualitative study. Cephalalgia 23 (2003) 892-900
151. Russell M.B., and Olesen J. The genetics of migraine without aura and migraine with aura. Cephalalgia 13 (1993) 245-248
152. Russell M.B., Rasmussen B.K., Thorvaldsen P., and Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 24 (1995) 612-618
153. Saetrum Opgaard O., Hasbak P., de Vries R., Saxena P.R., and Edvinsson L. Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. Eur J Pharmacol 397 (2000) 373-382
154. Salvatore C.A., Hershey J.C., Corcoran H.A., Fay J.F., Johnston V.K., Moore E.L., et al. Pharmacological characterization of MK-0974 [N-[(3R, 6 S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4, 5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324 (2008) 416-421
155. Schaeffer C., Vandroux D., Thomassin L., Athias P., Rochette L., and Connat J. Calcitonin gene-related peptide partly protects cultured smooth muscle cells from apoptosis induced by an oxidative stress via activation of ERK1/2 MAPK. Biochim Biophys Acta 1643 (2003) 65-73
156. Schaeffer H., and Weber M. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19 (1999) 2435-2444
157. Schindler J., Monahan J., and Smith W. p38 Pathway kinases as anti-inflammatory drug targets. J Dent Res 86 (2007) 800-811
158. Schoonman G.G., van der Grond J., Kortmann C., van der Geest R.J., Terwindt G.M., and Ferrari M.D. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 131 (2008) 2192-2200
159. Schytz H.W., Birk S., Wienecke T., Kruuse C., Olesen J., and Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132 (2009) 16-25
160. Seger R., and Krebs E. The MAPK signaling cascade. FASEB J 9 (1995) 726-735
161. Segond von Banchet G., Pastor A., Biskup C., Schlegel C., Benndorf K., and Schaible H.G. Localization of functional calcitonin gene-related peptide binding sites in a subpopulation of cultured dorsal root ganglion neurons. Neuroscience 110 (2002) 131-145
162. 1F receptor agonist LY334370. Cephalalgia 19 (1999) 851-858
163. 2-adrenoceptors in rat dorsal root ganglia. Pain 84 (2000) 319-330
164. Sinclair S.R., Kane S.A., Xiao A., Willson K.J., Xu Y., Hickey L., et al. MK-0974 oral CGRP antagonist inhibits capsaicin-induced increases in dermal microvascular blood flow. Headache 47 (2007) 811
165. Sternini C. Enteric and visceral afferent CGRP neurons. Targets of innervation and differential expression patterns. Ann N Y Acad Sci 657 (1992) 170-186
166. Storer R.J., Akerman S., and Goadsby P.J. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142 (2004) 1171-1181
167. 2-adrenergic receptor activation inhibits calcitonin gene-related peptide expression in cultured dorsal root ganglia neurons. Brain Res 782 (1998) 184-193
168. Suzuki N., Hardebo J.E., and Owman C. Origins and pathways of cerebrovascular nerves storing substance P and calcitonin gene-related peptide in rat. Neuroscience 31 (1989) 427-438
169. Tepper S.J., and Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs 10 (2009) 711-720
170. Thalakoti S., Patil V.V., Damodaram S., Vause C.V., Langford L.E., Freeman S.E., et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47 (2007) 1008-1023
171. Theoharides T.C., Donelan J., Kandere-Grzybowska K., and Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 49 (2005) 65-76
172. Thomsen L.L., Kruuse C., Iversen H.K., and Olesen J. A nitric oxide donor (nitroglycerin) induces genuine migraine attacks. Eur J Neurol 1 (1994) 73-80
173. Thomsen L.L., Iversen H.K., and Olesen J. Cerebral blood-flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia 15 (1995) 109-116
174. Tvedskov J.F., Lipka K., Ashina M., Iversen H.K., Schifter S., and Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58 (2005) 561-568
175. Tvedskov, J. F., TfeltHansen, P., Petersen, K. A., & Olesen, J. (2009). CGRP receptor blockade with olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate induced migraine. Cephalalgia (in press).
176. Uddman R., Edvinsson L., Ekman R., Kingman T., and McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62 (1985) 131-136
177. Ulrich V., Gervil M., Fenger K., Olesen J., and Russell M.B. The prevalence and characteristics of migraine in twins from the general population. Headache 39 (1999) 173-180
178. Ulrich V., Gervil M., and Olesen J. The relative influence of environment and genes in episodic tension-type headache. Neurology 62 (2004) 2065-2069
179. Ursell P.C., Ren C.L., and Danilo Jr. P. Anatomic distribution of autonomic neural tissue in the developing dog heart: II Nonadrenergic noncholinergic innervation by calcitonin gene-related peptide-immunoreactive tissue. Anat Rec 230 (1991) 531-538
180. Van der Schueren B.J., Blanchard R., and Murphy M.G. Effect of MK-0974, an oral CGRP antagonist, on the hemodynamic response to sublingual nitroglycerin. Headache 48 (2008) S63-S64
181. Van Rossum D., Hanisch U.K., and Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21 (1997) 649-678
182. Vause C.V., and Durham P.L. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem 110 (2009) 811-821
183. Verheggen R., Bumann K., and Kaumann A.J. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37). Br J Pharmacol 136 (2002) 120-126
184. Villalón C.M., Centurión D., Valdivia L.F., de Vries P., and Saxena P.R. Migraine: an updated review on pathophysiology, pharmacology, therapy and future trends. Curr Vasc Pharmacol 1 (2003) 71-84
185. Waugh D.J., Bockman C.S., Smith D.D., and Abel P.W. Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors. J Pharmacol Exp Ther 289 (1999) 1419-1426
186. Weiller C., May A., Limmroth V., Juptner M., Kaube H., Schayck R.V., et al. Brain stem activation in spontaneous human migraine attacks. Natl Med 1 (1995) 658-660
187. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79 (1999) 143-180
188. Wienecke T., Olesen J., Oturai P.S., and Ashina M. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 139 (2008) 106-116
189. Wiesenfeld-Hallin Z., Hokfelt T., Lundberg J.M., Forssmann W.G., Reinecke M., Tschopp F.A., et al. Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat. Neurosci Lett 52 (1984) 199-204
190. Willems E.W., Valdivia L.F., Villalón C.M., and Saxena P.R. Possible role of alpha-adrenoceptor subtypes in acute migraine therapy. Cephalalgia 23 (2003) 245-257
191. Williams T.M., Stump C.A., Nguyen D.N., Quigley A.G., Bell I.M., Gallicchio S.N., et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett 16 (2006) 2595-2598
192. Wimalawansa S.J. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17 (1996) 533-585
193. Wu D., Doods H., Arndt K., and Schindler M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem Soc Trans 30 (2002) 468-473
194. 2, 7]hCGRP-preferring receptor. Eur J Pharmacol 400 (2000) 313-319
195. Yu X.J., Li C.Y., Wang K.Y., and Dai H.Y. Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK. Regul Pept 137 (2006) 134-139
196. Zhang Z., Winborn C., Marquez de Prado B., and Russo A. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27 (2007) 2693-2703